Skip to main content
. 2023 May 3;14:1130442. doi: 10.3389/fimmu.2023.1130442

Figure 5.

Figure 5

Antitumor efficacy of CD19 CAR MLNK cells in vivo.(A) Schema of in vivo studies. Briefly, NSG mice received 1 × 105 Raji cells IV followed by 5 × 106 NK cell IV injection on day 3, containing 45% to 55% CAR positive NK cells or MLNK cells. (B) Body weight of mice were monitored every 2 days. (C) Representative FACS plots showing CAR NK cells, CAR MLNK cells and Raji cells in the peripheral blood on day 7 post Raji injection. (D) Summary data of human NK (CD56+ GFP-) cells and Raji (GFP+ CD56-) cells in the PB on day 7. (E) Tumor burden were monitored using IVIS, and representative data of the bioluminescence mice are shown. (F) The serum levels of IFN-γ on day 7 by ELISA were shown. (G) Kaplan-Meier survival curve of mice receiving tumor only (gray line, n=9), CAR NK cells (blue line, n=10), CAR MLNK cells (red line, n=11). Data was pooled from two independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001; ns, no significance.